Hillary Raynes
Neurology · New York, NYNPI 1346231859
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,329 of the $2,863 with a category attached, or 81.4%. 22 manufacturers reported payments, led by Livanova USA, Inc. at 32.5% of the total. 2025 is the largest year on record at $1,330, 7.2 times the $186 reported in 2019.
Across 92 payments — averaging $31.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$930
- UCB, Inc.$446
- Neurelis, Inc.$232
- Tris Pharma Inc$162
- Novartis$147
- SK Life Science, Inc.$143
- plus $804 from 16 others
What the payments were for
- Travel & lodging$43215%
- Food & beverage$2,32981%
- Education$20%
- Gifts$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 9 | $930 |
| UCB, Inc. | 22 | $446 |
| Neurelis, Inc. | 9 | $232 |
| Tris Pharma Inc | 9 | $162 |
| Novartis | 2 | $147 |
| SK Life Science, Inc. | 4 | $143 |
| J2 Bio-pharma LLC | 1 | $100 |
| Jazz Pharmaceuticals Inc. | 4 | $90 |
| Aquestive Therapeutics, Inc. | 4 | $77 |
| Supernus Pharmaceuticals, Inc. | 4 | $77 |
| Greenwich Biosciences, Inc. | 4 | $66 |
| Azurity Pharmaceuticals, Inc. | 3 | $61 |
| Sunovion Pharmaceuticals Inc. | 3 | $53 |
| Biomarin Pharmaceutical Inc. | 2 | $50 |
| Biocodex, Inc. | 2 | $40 |
| Orchard Therapeutics North America | 1 | $38 |
| Neos Therapeutics, LP | 2 | $35 |
| Ultragenyx Pharmaceutical Inc. | 1 | $29 |
| Travere Therapeutics, Inc. | 3 | $26 |
| Ironshore Pharmaceuticals Inc. | 1 | $22 |
| Upsher-smith Laboratories LLC | 1 | $21 |
| Eisai Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$732
- Fintepla$125
- AFINITOR$122
How this compares
$2,863 in reported general payments places this provider in the 65th percentile of 1,623 neurology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxcarbazepine | 28 | $1,045 |
| Levetiracetam | 22 | $262 |
Paid to pharmacies, not to this prescriber.
Other neurology in New York
- Stephen KriegerNew York$1.1M
- Sheng-Han KuoNew York$657K
- Timothy VartanianNew York$468K
- Steven WolfNew York$428K
- David DodickNew York$426K
- David SimpsonNew York$403K
- Fred LublinNew York$383K
- Alexander ShtilbansNew York$374K
- Andrew LassmanNew York$359K
- Brian ApatoffNew York$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.